Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: A 10-year follow-up study

Journal of Internal Medicine

Volumn 253, Issue 3, 2003, Pages 284-292

  Retterstol, Lars ^a,b   Paus, B ^b   Bohn, M ^a   Bakken, A ^a   Erikssen, J ^c   Malinow, M R ^c   Berg, K ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c NONE

Author keywords

Follow up studies; Homocysteine; Myocardial infarction; Prognosis; Risk factor

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; FEMALE; FOLLOW UP; HEART ARREST; HEART DEATH; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SMOKING; BLOOD; COHORT ANALYSIS; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; SUDDEN DEATH; SURVIVAL;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0037338573     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01096.x     Document Type: Article

References (33)

1. Genest JJ Jr, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16: 1114-9.
2. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
3. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
4. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997; 79: 799-801.
5. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
6. Folsom AR, Nieto FJ, McGovern PG et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-10.
7. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.
8. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-9.
9. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.
10. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
11. Omland T, Samuelsson A, Hartford M et al. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch Intern Med 2000; 160: 1834-40.
12. Kark JD, Selhub J, Adler B et al. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med 1999; 131: 321-30.
13. Bostom AG, Silbershatz H, Rosenberg IH et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-80.
14. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
15. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160: 422-34.
16. Bohn M, Berge KE, Bakken A, Erikssen J, Berg K. Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. Clin Genet 1993; 44: 292-7.
17. Thompson GR, Wilson P. Coronary Risk Factors and Their Assessment. London: Science Press. 1992, pp. 7.1-7.10.
18. Malinow MR, Kang SS, Taylor LM et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79: 1180-8.
19. Clauss A. Gerinnungs-physiologische Schnellmetode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
20. Eda S, Kaufmann J, Roos W, Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 1998; 12: 137-44.
21. Mangschau A, Rollag A, Jonsbu J, Lund KR. Congestive heart failure and ejection fraction in acute myocardial infarction. Acta Med Scand 1986; 220: 101-7.
22. Lentz SR, Sobey CG, Piegors DJ et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 24-9.
23. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
24. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
25. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-33.
26. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-9.
27. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-6.
28. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-600.
29. Dudman NP. An alternative view of homocysteine. Lancet 1999; 354: 2072-4.
30. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. Circ Res 1999; 84: 409-16.
31. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34: 2002-6.
32. Wilmink HW, Stroes ES, Erkelens WD et al. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000; 20: 185-8.
33. von Eckardstein A, Malinow MR, Upson B et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994; 14: 460-4.